Catheter Precision, Inc. (NYSE American:VTAK) Anno
Post# of 91

https://www.accesswire.com/837248/catheter-pr...-in-turkey
FORT MILL, SC / ACCESSWIRE / February 28, 2024 / Catheter Precision, Inc. (the "Company"

Catheter Precision's CEO, David Jenkins, said, "VIVO is an excellent choice for pre-procedure planning, especially in pediatric patients. VIVO is non-invasive and used prior to ventricular ablations, meaning that it can provide the physician with additional information specific to each patient and because it is non-invasive there is no additional risk when it is utilized. The utilization of VIVO in delicate patient populations like this continues to show the flexibility and many benefits of this innovative product."

